What is Treventis?
Treventis Corporation is a Canadian biotech start-up dedicated to addressing and preventing protein misfolding diseases through its innovative Common Conformational Morphology (CCM) technology. The company employs a patented discovery engine to pinpoint druggable active sites on misfolded protein targets. Its lead program, a collaboration with Takeda, focuses on creating anti-misfolding small molecules for Alzheimer's disease. Beyond Alzheimer's, Treventis is also pursuing therapeutic applications in oncology and other neurodegenerative conditions, supported by funding from the U.S. Department of Defense, demonstrating the broad applicability of its platform.
How much funding has Treventis raised?
Treventis has raised a total of $4.4M across 1 funding round:
Unspecified
$4.4M
Unspecified (2013): $4.4M, investors not publicly disclosed
What's next for Treventis?
With substantial enterprise-level backing and a strategic investment, Treventis is poised to accelerate its research and development pipeline. The company's focus on protein misfolding diseases, particularly its lead program targeting Alzheimer's in partnership with Takeda, positions it at the forefront of neurodegenerative disease treatment. Continued investment will likely fuel clinical trial progression and further exploration of its CCM technology across other indications such as ALS, Parkinson's disease, and cancer, solidifying its role as a key player in the biopharmaceutical sector.
See full Treventis company page
